United States · 
Who invested in FORE Biotherapeutics?
FORE Biotherapeutics's investors include SR One, OrbiMed, Wellington Management, Cormorant Asset Management and Medicxi, and 11 more on record. SR One led its latest round.
2026
$40MSeries D$67MSeries D
United States · Series D startup
Who invested in FORE Biotherapeutics
2 rounds we have observed, with the 16 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Raised 4 months ago
Follow FORE Biotherapeutics and see its new rounds in your feed. Start following
Funding summaryUpdated 5 Nov 2026
$108Mraised across 2 rounds since 2025, from 3 sources
$40MSeries D$67MSeries D
- Latest round
- Series D, $67MJul 2026
- Led by
- SR One and Medicxiand 1 more
- Step-upi
- 1.7×
- Investors
- 16 (3 led)
The funding story
Each circle is a round, placed by date and sized by amount. The line above is the running total.
- First round
- Series D, $40M May 2025
- Biggest round
- $67M Series D · Jul 2026
- Between rounds
- 14 months from the last two
The rounds
- Jul 2026Series D$67M12 new4 returning
SR OneLead
MedicxiLead
SymBiosisLead
OrbiMed
Wellington Management
Cormorant Asset Management
Novartis Venture Fund
Samsung
Cormorant Capital
LG- HBM Healthcare Investments
- Axil
Primer Ventures- 3B Capital
- TaiAx
- Windham Life Science Partners
Reported by Ventureburn and 1 other
- May 2025
Founders and team
From FORE Biotherapeutics's own website: 3 on the team.
- Michael ByrnesChief Financial Officer
- Rajeev DadooCOO and Managing Partner of SR One
- Dieter WeinandChairman of the Board
Who was in which round
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Everyone who backed them
HBM Healthcare InvestmentsVC firm1round
AxilGrowth equity1round
3B CapitalGrowth equity1round
TaiAxGrowth equity1round
Windham Life Science PartnersGrowth equity1round
Missing a round, or an investor who was in one? Tell us.
Also claim to have backed them
This firm lists FORE Biotherapeutics as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.
Quick answers about FORE Biotherapeutics
How much has FORE Biotherapeutics raised?
FORE Biotherapeutics has raised $108M across 2 rounds since 2025.
When did FORE Biotherapeutics last raise?
FORE Biotherapeutics's most recent round was a Series D of $67M in Jul 2026, led by SR One.
What was FORE Biotherapeutics's biggest round?
Its most recent round, $67M in Jul 2026, is also its largest on record.
Who backed FORE Biotherapeutics first?
FORE Biotherapeutics's first round on record, in May 2025, was backed by OrbiMed, Wellington Management and Cormorant Asset Management and 1 others.
What stage is FORE Biotherapeutics at?
FORE Biotherapeutics's latest named round is a Series D, in Jul 2026.
Where is FORE Biotherapeutics based?
FORE Biotherapeutics is based in the United States.
Who led FORE Biotherapeutics's rounds?
SR One led the Series D in 2026.
Companies like FORE Biotherapeutics
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.